Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
$79.29
$0.74(1.19%)
At close: 4:00 PM EST
$79.29
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$30.82 - $99.50
Previous CloseN/A
Volume41.94K
Average Volume (3M)537.54K
Market Cap
$3.06B
Enterprise Value$1.74B
Total Cash (Recent Filing)$615.92M
Total Debt (Recent Filing)$30.98M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Mar 27, 2026EPS Estimate
-1.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding37,750,160
10 Day Avg. Volume339,959
30 Day Avg. Volume537,537
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)3.95
Price to Sales (P/S)0.00
P/FCF Ratio-18.53
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.12K
Enterprise Value/Ebitda-10.76
Forecast
1Y Price Target
$120.20Price Target Upside51.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-6.9
Revenue Forecast (FY)$47.33M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DevelopmentPhase II RALLY-MF results showing consistent hepcidin suppression and strong hematologic responses for DISC-0974 support advancement to a pivotal anemia of myelofibrosis study and broaden clinical opportunity.
Financial Strength And Commercial ReadinessA solid cash position and active commercial planning increase the company's ability to fund launch preparations for bitopertin and continued development across the pipeline.
Regulatory ReviewCollaborative, high-energy interactions with the FDA and concentrated Division of Dermatology and Dentistry resources indicate regulators are prioritizing the bitopertin review and support a potential accelerated approval pathway.
Bears Say
Efficacy Skepticism And Approval RiskPublic skepticism from influential regulatory figures about the drug's efficacy could prompt added scrutiny or requests for more data, increasing the risk of approval delays or conditional requirements.
Market Reaction And Valuation PressureNotable share-price declines following media coverage suggest the market may have already discounted regulatory benefits, limiting upside until clearer, positive regulatory milestones are achieved.
Regulatory Politicization And Media RiskUnconfirmed articles alleging political interference in drug review processes create regulatory uncertainty that could undermine investor confidence and complicate the approval narrative.
Disc Medicine News
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $30.82 and its highest was $99.50 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $3.06B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Mar 27, 2026 which is in 77 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Nov 06, 2025. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.442 by -$0.328.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.75.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 37,750,160 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.442. Following the earnings report the stock price went down -1.483%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$120.20 (51.60% Upside)
$120.20 (51.60% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $91.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.78%
12-Months-Change
Fundamentals
Return on Equity
-34.78%
Trailing 12-Months
Asset Growth
27.33%
Trailing 12-Months
Company Description
Disc Medicine
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
IRON Stock 12 Month Forecast
Average Price Target
$120.20
▲(51.60% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
10.85% Insiders
22.40% Mutual Funds
41.84% Other Institutional Investors
15.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---